Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 W ELECTROLYTES versus PREMASOL 10 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN II 10 W ELECTROLYTES versus PREMASOL 10 IN PLASTIC CONTAINER.
AMINOSYN II 10% W/ ELECTROLYTES vs PREMASOL 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; electrolytes maintain osmotic and acid-base balance.
Provides essential amino acids for protein synthesis and maintenance of nitrogen balance.
1-2 g/kg/day (0.1-0.2 g/kg/hour) IV via central line as continuous infusion.
1-2 g/kg/day intravenously as a continuous infusion or in divided doses; typical starting dose for adults with normal renal function: 1 g/kg/day.
None Documented
None Documented
The terminal elimination half-life of individual amino acids varies but is generally short (range 0.5–2 hours) due to rapid uptake and metabolism. Clinically, the half-life of infused amino acids is not a relevant parameter for dosing; rather, infusion rate is adjusted to maintain nitrogen balance.
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for most amino acids, reflecting rapid metabolism and distribution. Clinically, this supports continuous infusion to maintain plasma amino acid levels.
Amino acids are primarily metabolized to urea and other nitrogenous waste products, which are excreted renally (90-95% of total nitrogen excreted as urea). Unmetabolized amino acids in plasma are also filtered and reabsorbed by the kidneys; negligible amounts are excreted unchanged (<5%). Biliary/fecal excretion is minimal (<2%).
Amino acids in Premasol 10% are metabolized and the nitrogen is eliminated primarily as urea via renal excretion (80-90%). A small fraction is excreted in feces (5-10%) and as ammonia in urine. Biliary excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution